Epidemiological surveys indicate that the incidence of inflammatory bowel disease (IBD) is
increasing rapidly with the continuous growth of the economy. A large number of studies …

The human gastrointestinal tract is inhabited by the largest microbial community within the
human body consisting of trillions of microbes called gut microbiota. The normal flora is the …

Inflammatory bowel disease can be caused by the dysfunction of the intestinal mucosal
barrier and dysregulation of gut microbiota. Traditional treatments use drugs to manage …

Reactive oxygen species (ROS) play vital roles in intestinal inflammation. Therefore,
eliminating ROS in the inflammatory site by antioxidant enzymes such as catalase and …

Background Alteration of the gut microbiota may contribute to the development of
inflammatory bowel disease (IBD). Epigallocatechin-3-gallate (EGCG), a major bioactive …

Immunotherapy is used to regulate systemic hyperactivation or hypoactivation to treat
various diseases. Biomaterial‐based immunotherapy systems can improve therapeutic …

Hyaluronic acid (HA) is a natural polymer, produced endogenously by the human body,
which has unique physicochemical and biological properties, exhibiting desirable …

A therapeutic strategy that targets multiple proinflammatory factors in inflammatory bowel
disease (IBD) with minimal systemic side effects would be attractive. Here, we develop a …

Although synthesized nanotherapeutics (NTs) are attractive for the oral treatment of colon
diseases, their clinical translations are constrained by the unsatisfactory therapeutic …

Antioxidant treatment strategy by scavenging reactive oxygen species (ROS) is a highly
effective disease treatment option. Nanozymes with multiple antioxidant activities can cope …